|
^^^^^^^^^%
These results were duplicated in
a similar study, below. Again, double the rate of sexual intercourse for the
testosterone group after 24 weeks.
Obstetrics & Gynecology
May 2005,
Vol. 105, Issue 5, Part 1, pp. 944-952
Testosterone Patch for Low Sexual Desire in Surgically Menopausal
Women: A Randomized Trial
Buster, John E. MD; Kingsberg, Sheryl A. PhD; Aguirre, Oscar MD; Brown, Candace PhD; Breaux, Jeffrey G. MD; Buch, Akshay
PhD; Rodenberg, Cynthia A. PhD; Wekselman, Kathryn RN, PhD; Casson, Peter MD
ABSTRACT:
OBJECTIVE: To assess the efficacy and safety of a 300 μg/d testosterone
patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women on concomitant estrogen therapy.
METHODS: Five hundred thirty-three women with hypoactive sexual desire disorder
who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter, double-blind,
placebo-controlled trial. Patients were randomly assigned to receive placebo or the testosterone patch twice weekly. The primary
efficacy endpoint was change from baseline at week 24 in the frequency of total satisfying sexual activity, measured by the
Sexual Activity Log. Secondary measures included sexual desire using the Profile of Female Sexual Function and personal distress
as measured by the Personal Distress Scale. Hormone levels, adverse events, and clinical laboratory measures were reviewed.
RESULTS: Total
satisfying sexual activity significantly improved in the testosterone patch group compared with placebo after 24 weeks (mean
change from baseline, 1.56 compared with 0.73 episodes per 4 weeks, P = .001). Treatment with the testosterone
patch also significantly improved sexual desire (mean change, 10.57 compared with 4.29, P < .001) and decreased
personal distress (P = .009). Serum free, total, and bioavailable testosterone concentrations increased from baseline.
Overall, adverse events were similar in both groups (P > .05). The incidence of androgenic adverse events was
higher in the testosterone group; most androgenic adverse events were mild.
CONCLUSION: In surgically menopausal women with hypoactive sexual desire disorder,
a 300 μg/d testosterone patch significantly increased satisfying sexual activity and sexual desire, while decreasing
personal distress, and was well tolerated through up to 24 weeks of use.
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
The
endocrinology of sexual arousal
J. Endocrinol.,
September 1, 2005; 186(3): 411 - 427.
S. R. Davis,
M. Moreau, R. Kroll, C. Bouchard, N. Panay, M. Gass, G. D. Braunstein, A. L. Hirschberg, C. Rodenberg, S. Pack, et al.
Testosterone
for Low Libido in Postmenopausal Women Not Taking Estrogen
N. Engl. J. Med., November 6, 2008;
359(19): 2005 - 2017.
ABSTRACT
Background The
efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women
not receiving estrogen therapy are unknown.
Methods We conducted
a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder
were randomly assigned to receive a patch delivering 150 or 300 µg of testosterone per day or placebo. Efficacy
was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants
followed for an additional year. The primary end point was the change from baseline to week 24 in the
4-week frequency of satisfying sexual episodes.
Results At 24
weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the
group receiving 300 µg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001{control group])
but not in the group receiving 150 µg per day (1.2 episodes, P=0.11). As compared with placebo, both doses
of testosterone were associated with significant increases in desire (300 µg per day, P<0.001; 150
µg per day, P=0.04) and decreases in distress (300 µg per day, P<0.001; 150 µg per day, P=0.04).
The rate of androgenic adverse events — primarily unwanted hair growth — was higher in the group
receiving 300 µg of testosterone per day than in the placebo group (30.0% vs. 23.1%). Breast cancer was diagnosed
in four women who received testosterone (as compared with none who received placebo); one of the four
received the diagnosis in the first 4 months of the study period, and one, in retrospect, had symptoms before
undergoing randomization.
Conclusions In
postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 µg of testosterone
per day resulted in a modest but meaningful improvement in sexual function. The long-term effects of testosterone,
including effects on the breast, remain uncertain. (ClinicalTrials.gov number, NCT00131495
For those who want to ready a highly technical, lengthy article
on the action of testosterone in the brain, click on link below
Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
The Journal of Neuroscience, October 11, 2006, 26(41):10332-10348;
doi:10.1523/JNEUROSCI.3369-06.2006
http://www.jneurosci.org/cgi/content/full/26/41/10332
http://journals.lww.com/greenjournal/Abstract/2005/05000/Testosterone_Patch_for_Low_Sexual_Desire_in.6.aspx
Obstetrics and Gynecology May 2005, Vol. 105, Issue 5, Part 1, pp. 944-952
Testosterone Patch for Low Sexual Desire in Surgically Menopausal Women: A Randomized Trial
Abstract
OBJECTIVE: To assess the efficacy and safety of a 300 μg/d
testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women on concomitant estrogen
therapy.
METHODS: Five hundred thirty-three women with hypoactive
sexual desire disorder who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter,
double-blind, placebo-controlled trial. Patients were randomly assigned to receive placebo or the testosterone patch twice
weekly. The primary efficacy endpoint was change from baseline at week 24 in the frequency of total satisfying sexual activity,
measured by the Sexual Activity Log. Secondary measures included sexual desire using the Profile of Female Sexual Function
and personal distress as measured by the Personal Distress Scale. Hormone levels, adverse events, and clinical laboratory
measures were reviewed.
RESULTS: Total satisfying sexual activity significantly
improved in the testosterone patch group compared with placebo after 24 weeks (mean change from baseline, 1.56 compared with
0.73 episodes per 4 weeks, P = .001). Treatment with the testosterone patch also significantly improved sexual
desire (mean change, 10.57 compared with 4.29, P < .001) and decreased personal distress
(P = .009).
Serum free, total, and bioavailable testosterone concentrations increased from baseline. Overall, adverse events were similar
in both groups (P >
.05). The incidence of androgenic adverse events was higher in the testosterone group; most androgenic adverse events were
mild.
CONCLUSION: In surgically menopausal women with
hypoactive sexual desire disorder, a 300 μg/d testosterone patch significantly increased satisfying sexual activity and
sexual desire, while decreasing personal distress, and was well tolerated through up to 24 weeks of use.
|
